Cargando…

Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34(+) Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia

SIMPLE SUMMARY: Despite a relationship between immune dysregulation and the course of myelodysplastic syndromes (MDS) has been discussed, a detailed understanding of this phenomenon is still missing. Therefore, multiplex analyses of bone marrow biopsies (BMB) from patients with MDS and secondary acu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bauer, Marcus, Vaxevanis, Christoforos, Al-Ali, Haifa Kathrin, Jaekel, Nadja, Naumann, Christin Le Hoa, Schaffrath, Judith, Rau, Achim, Seliger, Barbara, Wickenhauser, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825771/ https://www.ncbi.nlm.nih.gov/pubmed/33430322 http://dx.doi.org/10.3390/cancers13020186

Ejemplares similares

Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins
por: Bauer, Marcus, et al.
Publicado: (2020)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
por: Vaxevanis, Christoforos K., et al.
Publicado: (2022)

Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia
por: Ye, Dongjiu, et al.
Publicado: (2008)

Targeting the coding sequence: opposing roles in regulating classical and non-classical MHC class I molecules by miR-16 and miR-744
por: Friedrich, Michael, et al.
Publicado: (2020)

Correlation of the tumor escape phenotype with loss of PRELP expression in melanoma
por: Schäfer, Helene, et al.
Publicado: (2023)

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
por: Kenealy, Melita, et al.
Publicado: (2019)

Isolation and Characterization of CD34+ Blast-Derived Exosomes in Acute Myeloid Leukemia
por: Hong, Chang Sook, et al.
Publicado: (2014)

Computerized texture analysis of atypical immature myeloid precursors in patients with myelodysplastic syndromes: an entity between blasts and promyelocytes
por: Vido, Joyce R, et al.
Publicado: (2011)

TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma
por: Tretbar, Sandy, et al.
Publicado: (2019)

WT1 Expression Levels Combined with Flow Cytometry Blast Counts for Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Giudice, Valentina, et al.
Publicado: (2021)

Favorable outcomes of DDX41‐mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide
por: Tiong, Ing S., et al.
Publicado: (2023)

Identification and characterization of novel CD274 (PD‐L1) regulating microRNAs and their functional relevance in melanoma
por: Vaxevanis, Christoforos K., et al.
Publicado: (2022)

Establishment and Validation of an Updated Diagnostic FCM Scoring System Based on Pooled Immunophenotyping in CD34+ Blasts and Its Clinical Significance for Myelodysplastic Syndromes
por: Xu, Feng, et al.
Publicado: (2014)

Implications of the 5(th) Edition of the World Health Organization Classification and International Consensus Classification of Myeloid Neoplasm in Myelodysplastic Syndrome With Excess Blasts and Acute Myeloid Leukemia
por: Lee, Cheonghwa, et al.
Publicado: (2023)

Focal blast crisis in concomitant myelodysplastic syndrome and chronic myelogenous leukemia
por: Reap, Leo, et al.
Publicado: (2020)

Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome
por: Corrao, Kristen, et al.
Publicado: (2022)

Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome—excess blasts detected by next-generation sequencing technique
por: Owattanapanich, Weerapat, et al.
Publicado: (2021)

Pediatric chronic myeloid leukemia in myeloid blast crisis
por: Dey, Biswajit, et al.
Publicado: (2023)

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
por: Sébert, Marie, et al.
Publicado: (2019)

Epstein–Barr Virus—Associated Malignancies and Immune Escape: The Role of the Tumor Microenvironment and Tumor Cell Evasion Strategies
por: Bauer, Marcus, et al.
Publicado: (2021)

Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase
por: Yohanan, Binoy, et al.
Publicado: (2022)

Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia
por: Cross, Michael, et al.
Publicado: (2013)

Bullous Pemphigoid in an Elderly Patient with Myelodysplastic Syndrome and Refractory Anemia Coupled with Excess of Blast
por: Lee, Yin Yin, et al.
Publicado: (2011)

Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients
por: Grimm, Juliane, et al.
Publicado: (2022)

Proteome Changes in the Plasma of Myelodysplastic Syndrome Patients with Refractory Anemia with Excess Blasts Subtype 2
por: Majek, Pavel, et al.
Publicado: (2014)

Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome
por: Májek, Pavel, et al.
Publicado: (2012)

Correlation Between Bone Marrow Blasts Counts With Flow Cytometry and Morphological Analysis in Myelodysplastic Syndromes
por: Huang, Min, et al.
Publicado: (2017)

Pseudomonas aeruginosa ventriculitis following pancytopenia due to myelodysplastic syndrome with an excess of blasts type 2
por: Scorza, Carla Alexandra, et al.
Publicado: (2023)

Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias
por: Leone, Giuseppe, et al.
Publicado: (2008)

Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Kapoor, Sargam, et al.
Publicado: (2021)

Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes
por: Asayama, Toshio, et al.
Publicado: (2017)

Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
por: Serin, Istemi, et al.
Publicado: (2020)

Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine
por: Buettner, Ralf, et al.
Publicado: (2021)

Myeloid sarcoma of the Gingiva with myelodysplastic syndrome: A Case Report
por: Jin, Seong-Ho, et al.
Publicado: (2016)

Myelodysplastic Syndrome/Acute Myeloid Leukemia Arising in Idiopathic Erythrocytosis
por: Langabeer, Stephen E., et al.
Publicado: (2018)

Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias
por: Testa, Ugo, et al.
Publicado: (2020)

Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: Morelli, Emanuela, et al.
Publicado: (2021)

Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia
por: Woll, Petter S., et al.
Publicado: (2022)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Rahmé, Ramy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j46r19lnmdh2285hnjkll2l6st